The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Zoll Medical Corp. (NSDQ:ZOLL) posted strong second-quarter results, reporting a 15.5 percent increase in revenues and a 105 percent surge in Q2 profits.
The Billerica, Mass.-based resuscitation products provider reported revenues of $107.1 million for the three months ended March 31, compared with $92.7 million during the same period last year.
Ernie Whiton is not a person who lets stock options lay around without getting some exercise.
The CFO at Zoll Medical Corp. (NSDQ:ZOLL) is preparing to sell off another large slice of his company stock, disclosing plans this week to offer up to 90,000 shares through a series of pre-arranged sales beginning next month.
Whiton joined the Chelmsford, Mass.-based maker of defibrillators in January 1999, following a six-year stint at Ionics Inc. (now part of General Electric) in Watertown, Mass. He earns $280,000 in annual salary and holds a total of 107,750 vested options to buy Zoll stock priced between $11.26 and $23.05 a share, awarded through Zoll’s long-term equity incentive compensation plan.
Officials at Zoll Medical Corp. (NSDQ:ZOLL) say the company’s CPR training app for the iPhone has been downloaded more than 40,000 times.
Mark Totman, president of Bio-Detek Inc., a Pawtucket, R.I.-based subsidiary of Chelmsford, Mass.-based Zoll, told MassDevice that those downloads have come from more than 60 different countries.
In addition, Totman said, Zoll is giving the training app away for free during February to commemorate National Heart Awareness Month. The application normally costs about 99 cents, he said.
Zoll Medical Corp. (NSDQ:ZOLL) posted a 20.2 percent decline in net income during the first quarter, despite logging a 17.6 percent sales increase, hampered by still-slow capital spending.
The Chelmsford, Mass.-based resuscitation device maker reported net income of $2.3 million, or 11 cents per share, for the three months ended Jan. 3, compared with $2.9 million, or 14 cents per share, during Q1 2009. That’s despite sales of $105.2 million, compared with $89.5 million during the first quarter last year. The company had orders worth about $17 million in its pipeline at the end of the most recent quarter, more than double the amount it had at the end of Q1 2009.
U.S. Senate hopeful Scott Brown is no fan of the medical device tax — or the entire healthcare reform bill, for that matter.
On a campaign stop at Chelmsford, Mass.-based resuscitation device maker Zoll Medical Corp. (NSDQ:ZOLL), Brown promised he’d do all he could to kill the proposed 10-year, $20 billion levy on medical device makers contained in the Senate’s healthcare reform package.
